Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • News
  • FDA approves Beren’s Lembaz for Niemann-Pick disease type C
  • News

FDA approves Beren’s Lembaz for Niemann-Pick disease type C

FDA approved Beren's Lembaz for infantile-onset Niemann-Pick disease type C and Roche's Wilserdly in ESR1-mutated advanced breast cancer, while Isomorphic Labs raised $5 billion and Lilly signed a cancer deal worth up to $5.9 billion.
pharminent November 18, 2026

Pharminent · Daily Brief
November 18, 2026

Regulatory & Approvals

FDA approves Beren’s Lembaz for Niemann-Pick disease type C
The FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe, infantile-onset form of Niemann-Pick disease type C live longer.
FDA →

FDA approves Roche’s breast cancer pill Wilserdly
The FDA approved Roche’s Wilserdly (giredestrant) for ER-positive, ESR1-mutated advanced breast cancer. Analysts described the U.S. approval as a “key first step” in the launch, and Roche has said the drug could become its top-selling product.
BioPharma Dive →$RHHBY

White House withdraws Heidi Overton’s FDA commissioner nomination
The White House rescinded its nomination of Heidi Overton to serve as FDA Commissioner.
STAT →

FDA launches Global Reliance Disclosure Program for drug approvals
The FDA announced the Global Reliance Disclosure Program (GRDP), an initiative to change how the agency’s drug and biologic approval decisions are used by health authorities around the world.
FDA →

FDA approves Cosentyx for polymyalgia rheumatica
The FDA approved Cosentyx for polymyalgia rheumatica.
PharmExec →

HHS updates HIPAA privacy rule on patient record access
The federal health department updated the HIPAA privacy rule with a focus on supporting patients’ access to their own medical records, setting standards for sharing records with apps.
STAT →

Deals & Partnerships

Lilly signs cancer deal with Stipple Bio worth up to $5.9B
Eli Lilly entered a cancer partnership with Stipple Bio worth up to $5.9 billion. Stipple plans to start a Phase 1 trial of an antibody-drug conjugate for solid tumors in early 2027.
Pharmaceutical Technology →$LLY

Gilead signs royalty-free licensing deals for obeldesivir access
Gilead signed royalty-free licensing agreements intended to broaden access to its antiviral obeldesivir.
PharmExec →$GILD

Business & Finance

Isomorphic Labs raises $5B in Series C financing
Isomorphic Labs raised $5 billion in a Series C financing round to support development of its AI platform and advance its therapeutic candidates toward clinical evaluation.
Pharmaceutical Technology →

Marrow Therapeutics launches with $173M for blood disorder drugs
Marrow Therapeutics emerged with $173 million to develop transferrin receptor-targeted “Trojan horse” delivery of medicines for blood disorders, with sickle cell disease and beta thalassemia as its lead indications. Company executives said manufacturing and dosing advantages could make its medicine more broadly accessible worldwide.
MedCity News →

Teladoc launches employer contribution option for GLP-1 drugs
Teladoc launched an offering that allows employers to contribute toward the cost of GLP-1 medications.
MedCity News →

Pfizer’s CEO says China will be major competition by 2030
Pfizer CEO Albert Bourla said China will be his major competition by 2030, a month after the Chinese government unveiled a five-year biomedical plan to grow its pharmaceutical exports.
Pharmaceutical Technology →$PFE

Forwarded this? Get your copy free
Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.

Post navigation

Previous: FDA approves Roche’s oral SERD Wilserdly for breast cancer

Related Stories

  • News

FDA approves Roche’s oral SERD Wilserdly for breast cancer

pharminent November 17, 2026
  • News

FDA declines to approve Summit’s ivonescimab in lung cancer

pharminent November 16, 2026
  • News

Lilly Wins China Approval for Oral GLP-1 Weight Loss Drug

pharminent November 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.